The Role of Intensive Therapy and Autologous Blood and Marrow Transplantation for Chemotherapy‐Sensitive Relapsed and Primary Refractory Non‐Hodgkin’s Lymphoma: Identification of Major Prognostic Groups-Reference-Cited by-同舟云学术

The Role of Intensive Therapy and Autologous Blood and Marrow Transplantation for Chemotherapy‐Sensitive Relapsed and Primary Refractory Non‐Hodgkin’s Lymphoma: Identification of Major Prognostic Groups

Published:1996-03 Issue:4 Volume:92 Page:880-889
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:British Journal of Haematology

Author:

Prince H. Miles¹,Imrie Kevin¹,Crump Michael¹,Stewart A. Keith¹,Girouard Caroline¹,Colwill Richard¹,Brandwein Joseph¹,Tsang Richard W.¹,Scott J. Gerald¹,Sutton David M. C.¹,Pantalony Dominic¹,Carstairs Kelvin¹,Sutcliffe Simon B.¹,Keating Armand¹

Affiliation:

1. University of Toronto Autologous Blood and Marrow Transplant Program, The Toronto Hospital, Toronto, Ontario, Canada

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2141.1996.437976.x

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio;International Journal of Hematology;2024-03-16

2. Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma;Leukemia & Lymphoma;2023-01-19

3. Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2022-07

4. Disease characteristics of diffuse large B‐cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience;Hematological Oncology;2019-12-03

5. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT);Bone Marrow Transplantation;2019-09-20